Aptose Biosciences Inc. 8-K Report: Key Insights on Significant Event
Based on the provided section of the financial report, here are the key pieces of information and insights extracted:
- Entity Information:
- Company Name: Aptose Biosciences Inc.
- CIK Number: 0000882361 (Central Index Key used by the SEC)
- SEC File Number: 001-32001
- EIN: 98-1136802
- Address: 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, ON M5K 1E6
- Phone Number: 310-849-8060
- Filing Type:
- Form Type: 8-K, which is a report used to notify investors of significant events that may be of importance to shareholders.
- Filing Date:
- Date of Event: December 19, 2024 (the same date as the filing).
- Securities Information:
- Common Shares: The company has common shares with no par value.
- Ticker Symbol: APTO
- Exchange: NASDAQ
- Financial Units:
- The financial information is reported in USD (United States Dollars).
- There is also a measure of shares indicated.
Insights:
- The filing is relevant for investors interested in Aptose Biosciences, as it indicates a significant event that warrants disclosure.
- The company operates in the biotechnology sector, as inferred from its name, which could indicate potential fluctuations based on clinical trials, regulatory approvals, or market conditions.
- The absence of additional context or details about the specific event in this excerpt suggests that further investigation into the full 8-K filing may be necessary to understand the implications of the reported event on the company’s operations and stock performance.
This summary provides a foundational understanding of the company’s reporting status and pertinent identifiers for further analysis.